以临床价值为导向的抗肿瘤药物临床研发指导原则

2021-11-15 国家药品监督管理局药品审评中心(CDE) CDE

为落实以临床价值为导向,以患者为核心的研发理念,促进抗肿瘤药科学有序的开发,在国家药品监督管理局的部署下,药审中心组织制定了《以临床价值为导向的抗肿瘤药物临床研发指导原则》(见附件)。根据《国家药监局

中文标题:

以临床价值为导向的抗肿瘤药物临床研发指导原则

发布日期:

2021-11-15

简要介绍:

为落实以临床价值为导向,以患者为核心的研发理念,促进抗肿瘤药科学有序的开发,在国家药品监督管理局的部署下,药审中心组织制定了《以临床价值为导向的抗肿瘤药物临床研发指导原则》(见附件)。根据《国家药监局综合司关于印发药品技术指导原则发布程序的通知》(药监综药管〔2020〕9号)要求,经国家药品监督管理局审查同意,现予发布,自发布之日起施行。

       特此通告。

                                                                                                                                                                           国家药监局药审中心

                                                                                                                                                                            2021年11月15日

相关资料下载:
[AttachmentFileName(sort=1, fileName=img1.pdf)] GetToolGuiderByIdResponse(projectId=1, id=9fa5f1c002266e0c, title=以临床价值为导向的抗肿瘤药物临床研发指导原则, enTitle=, guiderFrom=CDE, authorId=0, author=, summary=为落实以临床价值为导向,以患者为核心的研发理念,促进抗肿瘤药科学有序的开发,在国家药品监督管理局的部署下,药审中心组织制定了《以临床价值为导向的抗肿瘤药物临床研发指导原则》(见附件)。根据《国家药监局, cover=, journalId=0, articlesId=null, associationId=1936, associationName=国家药品监督管理局药品审评中心(CDE), associationIntro=国家药品监督管理局药品审评中心(CDE), copyright=0, guiderPublishedTime=Mon Nov 15 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>为落实以临床价值为导向,以患者为核心的研发理念,促进抗肿瘤药科学有序的开发,在国家药品监督管理局的部署下,药审中心组织制定了《以临床价值为导向的抗肿瘤药物临床研发指导原则》(见附件)。根据《国家药监局综合司关于印发药品技术指导原则发布程序的通知》(药监综药管〔2020〕9号)要求,经国家药品监督管理局审查同意,现予发布,自发布之日起施行。</p> <p>&nbsp; &nbsp; &nbsp; &nbsp;特此通告。</p> <p>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 国家药监局药审中心</p> <p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2021年11月15日</p>, tagList=[TagDto(tagId=119, tagName=肿瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=30, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5389, appHits=38, showAppHits=0, pcHits=1133, showPcHits=5351, likes=0, shares=4, comments=2, approvalStatus=1, publishedTime=Fri Nov 19 20:29:28 CST 2021, publishedTimeString=2021-11-15, pcVisible=1, appVisible=1, editorId=4754896, editor=小小医者, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=小小医者, createdTime=Fri Nov 19 20:29:22 CST 2021, updatedBy=4754896, updatedName=小小医者, updatedTime=Sat Jan 06 20:07:49 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=img1.pdf)])
img1.pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1072610, encodeId=ca1c10e26107c, content=抓紧看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Sun Nov 21 21:03:30 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071971, encodeId=35d710e19713e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Nov 20 06:53:31 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
    2021-11-21 JZ Yang

    抓紧看看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1072610, encodeId=ca1c10e26107c, content=抓紧看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Sun Nov 21 21:03:30 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071971, encodeId=35d710e19713e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Nov 20 06:53:31 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
    2021-11-20 微探

    学习学习

    0